These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 28602029)

  • 21. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
    Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
    Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
    Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
    J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.
    Sideras K; Biermann K; Yap K; Mancham S; Boor PPC; Hansen BE; Stoop HJA; Peppelenbosch MP; van Eijck CH; Sleijfer S; Kwekkeboom J; Bruno MJ
    Int J Cancer; 2017 Aug; 141(3):572-582. PubMed ID: 28470686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer.
    Yoshida S; Ito Z; Suka M; Bito T; Kan S; Akasu T; Saruta M; Okamoto M; Kitamura H; Fujioka S; Misawa T; Akiba T; Yanagisawa H; Sugiyama H; Koido S
    Cancer Invest; 2019; 37(9):463-477. PubMed ID: 31490702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
    Nomi T; Sho M; Akahori T; Hamada K; Kubo A; Kanehiro H; Nakamura S; Enomoto K; Yagita H; Azuma M; Nakajima Y
    Clin Cancer Res; 2007 Apr; 13(7):2151-7. PubMed ID: 17404099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung.
    Hirai A; Yoneda K; Shimajiri S; Kuroda K; Hanagiri T; Fujino Y; Tanaka F
    J Thorac Cardiovasc Surg; 2018 Jan; 155(1):382-392.e1. PubMed ID: 28711324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
    Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
    Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
    Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
    Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
    Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.
    Takahashi D; Kojima M; Suzuki T; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Ikeda M; Nakatsura T; Ochiai A; Nagino M
    Sci Rep; 2018 Sep; 8(1):13166. PubMed ID: 30177687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.